📊 INTS Key Takeaways
Is Intensity Therapeutics, Inc.. (INTS) a Good Investment?
Intensity Therapeutics is a pre-commercial stage biotech company with an exceptionally strong balance sheet (83% of assets in cash, zero debt) and improving losses, but lacks any revenue generation and continues to burn cash. The solid financial foundation provides runway (~5.7 years at current burn rate), yet future viability depends entirely on clinical/product pipeline success, which cannot be assessed from financial data alone.
Intensity Therapeutics remains a pre-revenue biotech with persistent operating and net losses, negative cash flow, and deeply negative returns on equity and assets, which makes the fundamental profile weak despite some year-over-year loss improvement. Its balance sheet is currently a relative strength, with nearly all assets held in cash, no long-term debt, and strong liquidity, but the business still depends on converting that cash into clinical and commercial progress before runway tightens.
Why Buy Intensity Therapeutics, Inc.. Stock? INTS Key Strengths
- Fortress balance sheet with $10.2M cash against $2.3M liabilities and zero debt
- Excellent liquidity position (4.86x current and quick ratios)
- Improving loss trajectory year-over-year (net income loss decreased 28.7%, EPS improved 70.7%), indicating operational discipline
- Strong liquidity with $11.92M in cash and current and quick ratios of 5.92x
- No long-term debt and minimal leverage reduce balance sheet risk
- Net loss improved year over year, indicating some cost-control or expense timing benefit
INTS Stock Risks: Intensity Therapeutics, Inc.. Investment Risks
- Complete lack of revenue; pre-commercial development stage with uncertain commercialization timeline
- Ongoing operating and free cash flow burn (-$1.8M annually) with no path to profitability visible
- Minimal insider activity (1 Form 4 filing in 90 days) suggests limited insider confidence or engagement
- High execution risk inherent to biotech sector; clinical trial failures could rapidly deplete cash runway
- No revenue base means growth quality and commercial viability are still unproven
- Operating cash burn of $9.23M materially pressures cash runway
- Very negative ROE and ROA show poor current capital efficiency and asset productivity
Key Metrics to Watch
- Cash burn rate trends and runway extension/contraction
- Clinical trial progress and FDA regulatory milestones
- Gross margin upon revenue generation and path to positive operating cash flow
- Quarterly operating cash burn relative to cash balance
- Any transition from pre-revenue status to sustainable collaboration, licensing, or product revenue
Intensity Therapeutics, Inc.. (INTS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.86x current ratio provides a solid financial cushion.
INTS Profit Margin, ROE & Profitability Analysis
INTS vs Healthcare Sector: How Intensity Therapeutics, Inc.. Compares
How Intensity Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Intensity Therapeutics, Inc.. Stock Overvalued? INTS Valuation Analysis 2026
Based on fundamental analysis, Intensity Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Intensity Therapeutics, Inc.. Balance Sheet: INTS Debt, Cash & Liquidity
INTS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Intensity Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-29.24 indicates the company is currently unprofitable.
INTS Revenue Growth, EPS Growth & YoY Performance
Intensity Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
INTS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Intensity Therapeutics, Inc.. (CIK: 0001567264)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INTS
What is the AI rating for INTS?
Intensity Therapeutics, Inc.. (INTS) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INTS's key strengths?
Claude: Fortress balance sheet with $10.2M cash against $2.3M liabilities and zero debt. Excellent liquidity position (4.86x current and quick ratios). ChatGPT: Strong liquidity with $11.92M in cash and current and quick ratios of 5.92x. No long-term debt and minimal leverage reduce balance sheet risk.
What are the risks of investing in INTS?
Claude: Complete lack of revenue; pre-commercial development stage with uncertain commercialization timeline. Ongoing operating and free cash flow burn (-$1.8M annually) with no path to profitability visible. ChatGPT: No revenue base means growth quality and commercial viability are still unproven. Operating cash burn of $9.23M materially pressures cash runway.
What is INTS's revenue and growth?
Intensity Therapeutics, Inc.. reported revenue of N/A.
Does INTS pay dividends?
Intensity Therapeutics, Inc.. does not currently pay dividends.
Where can I find INTS SEC filings?
Official SEC filings for Intensity Therapeutics, Inc.. (CIK: 0001567264) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INTS's EPS?
Intensity Therapeutics, Inc.. has a diluted EPS of $-0.96.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INTS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Intensity Therapeutics, Inc.. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INTS stock overvalued or undervalued?
Valuation metrics for INTS: ROE of -24.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INTS stock in 2026?
Our dual AI analysis gives Intensity Therapeutics, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INTS's free cash flow?
Intensity Therapeutics, Inc..'s operating cash flow is $-1.8M, with capital expenditures of N/A.
How does INTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -24.4% (avg: 15%), current ratio 4.86 (avg: 2).